Difference between revisions of "Tuberculosis"
m (Protected "Tuberculosis" ([edit=sysop] (indefinite) [move=sysop] (indefinite))) |
|||
| Line 15: | Line 15: | ||
==Guidance== | ==Guidance== | ||
====Unacceptable==== | ====Unacceptable==== | ||
| − | Currently infected | + | |
| + | Currently infected | ||
Less than 2 years from completion of treatment; | Less than 2 years from completion of treatment; | ||
| − | |||
| + | Otherwise may be acceptable following discussion with medical officer. | ||
| + | |||
| + | |||
| + | ===Justification for Guidance=== | ||
| + | There are no documented case reports of tuberculosis (TB) transmission via blood transfusion or HPC transplantation. However, TB is one of the most common bacterial infections transmitted via solid organ transplantation. There is also a known risk of reactivating pre-existing latent infection in HPC transplant recipients, which is mainly seen in countries with an indigenous risk of TB. | ||
| + | The lack of reports of TB transmission via blood despite the known blood phase of TB infection and the worldwide prevalence of TB suggests that the risk of blood transmission – if it exists – must be extremely low. Extrapolating this assumption to HPC, however, should be done with caution because TB can infect bone and has been detected in bone marrow biopsies of infected patients. A recent study even suggests that bone marrow stem cells are an important reservoir of latent infection. | ||
| + | In this context, the precautionary stance of the current 2-year deferral period following successful treatment of infection seems justified, and is consistent with widely-utilised blood donor selection guidelines (eg the Council of Europe Guide to the preparation, use and quality assurance of blood components). | ||
| − | |||
==Pseudonyms or Related Conditions== | ==Pseudonyms or Related Conditions== | ||
| Line 32: | Line 38: | ||
==Version== | ==Version== | ||
| − | Version 1, Edition | + | Version 1, Edition 2 |
====Date of Last Update==== | ====Date of Last Update==== | ||
| − | + | 9 June 2016 | |
Latest revision as of 12:34, 9 June 2016
Contents
Acceptability at Recruitment
QUALIFIED
Acceptability at CT / Work-Up
QUALIFIED
Individual at Risk
Recipient
Explanation of Condition
Infection, typically in the lungs, caused by the bacterium mycobacterium tuberculosis.
See also Tuberculosis
Guidance
Unacceptable
Currently infected
Less than 2 years from completion of treatment;
Otherwise may be acceptable following discussion with medical officer.
Justification for Guidance
There are no documented case reports of tuberculosis (TB) transmission via blood transfusion or HPC transplantation. However, TB is one of the most common bacterial infections transmitted via solid organ transplantation. There is also a known risk of reactivating pre-existing latent infection in HPC transplant recipients, which is mainly seen in countries with an indigenous risk of TB. The lack of reports of TB transmission via blood despite the known blood phase of TB infection and the worldwide prevalence of TB suggests that the risk of blood transmission – if it exists – must be extremely low. Extrapolating this assumption to HPC, however, should be done with caution because TB can infect bone and has been detected in bone marrow biopsies of infected patients. A recent study even suggests that bone marrow stem cells are an important reservoir of latent infection. In this context, the precautionary stance of the current 2-year deferral period following successful treatment of infection seems justified, and is consistent with widely-utilised blood donor selection guidelines (eg the Council of Europe Guide to the preparation, use and quality assurance of blood components).
Pseudonyms or Related Conditions
TB
Consumption
Version
Version 1, Edition 2
Date of Last Update
9 June 2016
